 Phenylurea Compounds
"Phenylurea Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D010671
|
| MeSH Number(s) |
D02.948.684
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Phenylurea Compounds".
Below are MeSH descriptors whose meaning is more specific than "Phenylurea Compounds".
This graph shows the total number of publications written about "Phenylurea Compounds" by people in this website by year, and whether "Phenylurea Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 2 | 2 | | 2006 | 0 | 5 | 5 | | 2007 | 0 | 3 | 3 | | 2008 | 0 | 3 | 3 | | 2009 | 0 | 7 | 7 | | 2010 | 0 | 6 | 6 | | 2011 | 1 | 5 | 6 | | 2012 | 3 | 1 | 4 | | 2013 | 1 | 1 | 2 | | 2014 | 4 | 0 | 4 | | 2015 | 1 | 0 | 1 | | 2016 | 2 | 1 | 3 | | 2018 | 3 | 1 | 4 | | 2019 | 0 | 2 | 2 | | 2021 | 2 | 1 | 3 | | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Phenylurea Compounds" by people in Profiles.
-
Stewart EA, Lukes AS, Venturella R, Arjona Ferreira JC, Li Y, Hunsche E, Wagman RB, Al-Hendy A. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials. Obstet Gynecol. 2022 06 01; 139(6):1070-1081.
-
Ali M, Chen HY, Chiang YF, Badary OA, Hsia SM, Al-Hendy A. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother. 2022 Mar; 23(4):421-429.
-
Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, Tennøe ØK, Richards D, Sweis RF, Courtright J, Heinrich D, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJ. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021 07; 22(7):946-958.
-
Ackroyd SA, Huang ES, Kurnit KC, Lee NK. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. Gynecol Oncol. 2021 08; 162(2):249-255.
-
Al-Hendy A, Lukes AS, Poindexter AN, Venturella R, Villarroel C, Critchley HOD, Li Y, McKain L, Arjona Ferreira JC, Langenberg AGM, Wagman RB, Stewart EA. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. N Engl J Med. 2021 02 18; 384(7):630-642.
-
Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 06; 20(6):849-861.
-
Lee EEL, Bezanilla F. Methodological improvements for fluorescence recordings in Xenopus laevis oocytes. J Gen Physiol. 2019 02 04; 151(2):264-272.
-
Yu X, Liu F, Zeng L, He F, Zhang R, Yan S, Zeng Z, Shu Y, Zhao C, Wu X, Lei J, Zhang W, Yang C, Wu K, Wu Y, An L, Huang S, Ji X, Gong C, Yuan C, Zhang L, Feng Y, Huang B, Liu W, Zhang B, Dai Z, Wang X, Liu B, Haydon RC, Luu HH, Gan H, He TC, Chen L. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells. Cell Physiol Biochem. 2018; 47(3):957-971.
-
Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D. Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Br J Cancer. 2018 04; 118(8):1042-1050.
-
Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clin Cancer Res. 2018 05 15; 24(10):2294-2303.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|